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Patient involvement in the development of
patient-reported outcome measures: The
developers’ perspective
Bianca Wiering1* , Dolf de Boer2 and Diana Delnoij1
Abstract
Background: Patient-reported outcome measures (PROMs) are increasingly used in health care. To capture the
patient’s perspective, patient involvement in PROM development is needed. As earlier research showed varying
degrees of patient involvement in PROM development, this study aimed to investigate why PROM developers do
or do not involve patients, how patients can be successfully involved and what the negative aspects and benefits
of patient involvement are.
Methods: PROM developers who, according to an earlier scoping review, involved patients in at least two phases
of PROM development or did not involve patients at all, were contacted for a telephone interview. The interviews
were recorded, transcribed and analysed using a general inductive approach.
Results: From the PROM developers who involved patients, 21 developers were interviewed and three answered
questions via e-mail. Most developers considered patient involvement necessary to create a valid questionnaire and
relied on guidelines, personal experience and practical considerations for choosing a qualitative method. Negative
aspects of patient involvement were mainly time investment and budget impact. One developer who did not
involve patients was interviewed. Two developers sent back answers via e-mail. These developers did not involve
patients because of limited resources or because no benefits were expected.
Conclusion: Although PROM developers agree that patient involvement is necessary, a lack of resources can be a
stumbling block. Most developers rely on guidelines, personal experience or practical considerations for choosing a
qualitative method. Although this may be a good place to start, to optimize patient involvement developers should
explicitly think about which methods would suit their study.
Keywords: Patient-reported outcome measures, Patient participation, Questionnaire development procedures,
Qualitative research
Background
Patient-reported outcome measures (PROMs) are ques-
tionnaires which measure patients’ perspectives on
health outcomes [1, 2]. PROMs may be used to inform
patients of the performance of treatments and health
care professionals, improve the care of individual pa-
tients, assist health care purchasers and reward perform-
ance in pay for performance schemes [2–5]. PROMs are
increasingly assigned these important tasks of measuring
performance, treatment progress and quality of care in
health care systems such as the English National Health
Service (NHS) [2, 4], the American Centers for Medicare
and Medicaid Services (CMS) [6], the Dutch and the
Swedish health care system [7].
As PROMs are meant to reflect the patient’s perspec-
tive, the aim should be to use valid PROMs which truly
reflect this perspective. Patient involvement throughout
the development of PROMs is therefore essential [8–13].
Patient involvement can have a great impact on the
questionnaire as the relevance of outcomes and the
comprehensibility of the questionnaire can only be de-
termined by patients [12, 14–19]. Furthermore, patients
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may fail to complete the questionnaire if the question-
naire does not sufficiently reflect the patient’s perspec-
tive. A lack of patient involvement may have a negative
influence on the validity, sensitivity and response of a
questionnaire [13, 20].
However, although patient involvement in PROM
development has been recommended by researchers
[8–12, 21], and has also become a requirement of the
US Food and Drug Administration (FDA) [22], many
PROMs appear not to have been developed with pa-
tient input [9, 23, 24]. A scoping review of 193
PROMs looking at whether and to what extent pa-
tients are involved in the development of PROMs,
suggests that in over a quarter of the included papers
describing the development of a PROM, no patient
involvement was recorded. Furthermore, the level of
patient involvement in the remaining PROMs varied
greatly, from feedback forms to focus groups, inter-
views and cognitive interviews [24]. Another review of
42 PROMs for rheumatoid arthritis showed that
PROMs only minimally covered personal factors
which determine functioning and the individuals’ ex-
perience of disability according to the International
Classification of Functioning, Disability and Health
(ICF) and which were deemed important by patients
[25]. Other studies which investigated patient involve-
ment in a small number of PROMs suggest a complete
lack of patient involvement [23], conceptual difficulties
and questionnaire design problems. These problems
might have been prevented by involving patients in
the development process [9].
Apparently, not all PROM developers choose to in-
volve patients in the development of their PROM. Be-
sides, if a developer does decide to involve patients,
there is a great variety in the levels and methods of in-
volving patients. Although many benefits may be gained
by involving patients [26], research suggests that devel-
opers also need to consider slightly less positive conse-
quences such as the costs associated with patient
involvement [12, 26]. Additionally, there is no perfect
method to involve patients, as fairly little is known about
which methods are the most successful and which cir-
cumstances are needed for achieving optimal outcomes
[27]. Decisions that need to be made, such as whether
patients should be involved, to what extent patients
should be involved, and which methods should be used
to involve patients, appear to be mostly based on the ex-
periences and opinions of the researchers, the organisa-
tion they belong to, or the regulations or guidelines they
adhere to such as the US Food and Drug Administration
[22] or PROMIS (Patient-Reported Outcomes Measure-
ment Information System) [28].
However, as most professionals involved in PROM de-
velopment deal with similar decisions, it is necessary
that more insight is gained in how patients can be suc-
cessfully involved in PROM development and what
kind of benefits and costs of patient involvement are
experienced by PROM developers. By looking at suc-
cessful involvement, we are not necessarily interested
in how patients were involved, as this was also re-
corded in an earlier scoping review [24]. The focus lies
instead on how developers chose their methods, and
how they experienced using these methods. Such an
overview may help PROM developers make a more in-
formed decision regarding patient involvement. This
qualitative study therefore aimed to gather the views
of PROM developers, who did and did not involve pa-
tients, regarding patient involvement and its negative
aspects and benefits. Our research questions are:
According to the interviewed PROM developers:
1 Why did certain developers involve patients and
others did not?
2 How are patients successfully involved in the
development of PROMs?
3 What do patients contribute to the development of
PROMs?
4 What are negative aspects of patient involvement?
Methods
Participants
PROM developer recruitment was based on the list of
PROMs made for an earlier review [24]. The list was
composed by systematically searching the databases
PubMed, Embase, MEDLINE and the Cochrane Meth-
odology Register for papers describing new PROM de-
velopments. Patient involvement in three phases of
PROM development was recorded. For the present
study PROM developers were contacted who, according
to the review, involved patients in at least two phases
of development or did not involve patients at all. Pa-
tient involvement during at least two development
phases was chosen because involving patients during
two or more development phases means that devel-
opers have extensively involved patients, usually using
several methods. Developers are therefore able to dis-
cuss several patient involvement experiences and com-
pare methods in terms of usefulness and experienced
problems. Developers who involved patients during less
than two development phases were not included, as we
did not think they would provide additional and unique
information in addition to the experience of developers
who involved patients in multiple phases of develop-
ment. Recruitment was limited to the PROM study
publication dates between 2008 and May 2014 to en-
sure good remembrance of the development process.
The author named as contact in the publication in-
cluded in the review was contacted.
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Procedure
A list of questions was drafted to guide the interview
process (Tables 1 and 2). The questions were tested in
three pilot interviews with researchers who had experience
with patient involvement during questionnaire develop-
ment. No changes were made to the list of questions.
PROM developers were sent an e-mail asking whether
we could contact them via telephone for some questions
regarding patient involvement during the development
of a certain questionnaire. Reminders were sent a few
weeks later. If PROM developers agreed to a telephone
interview, a questionnaire (Tables 1 and 2) was sent and
an appointment was scheduled. If PROM developers
answered the questions via e-mail, an e-mail was sent
informing the developers of the purpose of our study. In
this e-mail we also asked them to consent to the use of
the information for a paper. PROM developers who
agreed to a telephone appointment were phoned at the
scheduled time and date and were informed of the pur-
pose of our study. They were asked to consent to the re-
cording of the interview and the use of the information
given during the interview for a paper. The conversation
and informed consent were recorded. A semi-structured
approach [29] was used for the interviews. Although the
questions were used to guide the conversation, room was
created for other topics. Transcripts of the interviews were
sent to the PROM developers for approval. 17 of the 22
developers returned their transcript with no or small text-
ual alterations. One developer added some text further
explaining his/her methods.
Analysis
The interviews were transcribed verbatim, after which
the transcriptions were analysed using a general induct-
ive approach for analysis of qualitative evaluation data
[30]. Segments of the interview text were coded closely
following the meaning of the segments, after which the
segments were grouped into subthemes and themes. For
example, when asked for the difficulties of patient
Table 1 Questions used as interview guide for interviews with
developers who involved patients
Questions for developers who involved patients
Patient recruitment
-Why did you decide to involve patients in the development of your
questionnaire?
-How many patients were involved in your development process?
-How did you decide how many patients you wanted to involve?
-How did you recruit the patients who were involved in your study?
-Did you have any difficulties with the recruitment of patients?
-Would you consider the patients who were involved a good
representation of the patient group?
Methods of involving patients
-How many methods did you use to involve patients in the
development of your questionnaire?
-During which development phases did you involve patients?
-Which methods did you use to involve patients?
-How did you decide which methods to use?
-The participation ladder of decision making in health care consists of
three steps. At the first step patients are involved as consultants. At
the second step patients are considered partners and at the third
step patients have a dominant role. Which step of the ladder
describes the position of the patients in your development process
the most accurate?
-Did you have any difficulties with involving patients in your
development process?
-If focus groups were used, how many focus groups were organised
and how many patients were involved per focus group?
-If interviews were used, how many interviews took place?
-Was a specific method used to interview the patients?
-If cognitive interviews were used, how many interviews took place?
-If another method was used; how many patients were involved?
-Which method was the most successful and why?
-Which method was the least successful and why?
Benefits and negative aspects of patient involvement
-Did patient involvement influence the questionnaire in any way?
-If you could go through the development process again, would you
change anything concerning patient involvement?
-Were there any benefits from involving patients? What kind of benefits?
-Did you perceive any negative aspects concerning patient
involvement? What kind of negative aspects?
-In hindsight, was there anything that could have been done to
prevent these negative aspects?
-Did the benefits outweigh the costs?
-Would you recommend involving patients during the development
process?
Table 2 Questions used as interview guide for interviews with
developers who did not involve patients
Questions for developers who did not involve patients
-Was involving patients in the development of the questionnaire
actively considered?
-Was there anything you expected to gain from patient involvement?
-Where there any negative consequences you expected to experience
regarding patient involvement?
-What were the main reasons for not involving patients?
-Would you consider the questionnaire relevant for patients?
-Could the questionnaire have been improved by involving patients?
-If you would develop a new questionnaire, would you involve patients?
-How did you make sure that patients interpreted the questions as they
were intended?
-How did you make sure that patients could complete the
questionnaire?
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involvement, a developer explained that patient involve-
ment is costly and takes time. The subthemes would be
‘costs’ and ‘time’. All subthemes describing difficulties or
challenges would be grouped under the theme ‘chal-
lenges of patient involvement’. The transcripts were ana-
lysed using ATLAS.ti, version 7 [31]. All interviews were
analysed by author BW. The first three interviews were
checked by author DD to ensure that no relevant infor-
mation was missed and the coding matched her under-
standing of the content. Five interviews were double
coded by authors BW and DB to check the reliability
and transparency of the coding. Any differences were
discussed until agreement was reached. Finally, a content
check was performed where authors DD and DB each
read 10 interviews and made sure that the interviews
were well reflected in the results section.
Results
Response
Forty-one PROM developers who involved patients and
16 PROM developers who did not involve patients were
invited to participate. Initially 22 PROM developers who
involved patients agreed to an interview. Seventeen de-
velopers who involved patients did not respond to the
invitation. One interview took place at the developer’s
place of work, the other interviews were held via tele-
phone. One interview was joined by another developer
involved with the instrument. This resulted in 21 inter-
views. Additionally, three PROM developers who in-
volved patients sent back the completed questionnaire.
This is a response rate of 58.5%. Of the 16 PROM devel-
opers who did not involve patients only two developers
sent back a completed questionnaire and two developers
agreed to an interview. Twelve developers did not re-
spond to the invitation. After the interviews had taken
place one PROM developer withdrew his/her consent.
This is a response rate of 18.8%. Most participants were
native English speakers from the United Kingdom, the
United States, Canada and New Zealand. One partici-
pant came from Germany. Most non-respondents also
came from the United States or the United Kingdom.
However, as ten out of eleven non-native English
speakers declined our invitation, there was a difference
in countries of residence between respondents and
non-respondents. The average publication date of re-
spondents was 2011, which was similar to the average
publication date of non-respondents.
Themes
The major themes that were identified during the ana-
lysis of the interviews concerned the motivation for in-
volving patients, motivation for not involving patients,
requirements for patient involvement, the benefits of
patient involvement, the overall challenges of involving
patients, recruitment methods, recruitment challenges,
methods to involve patients, method motivation, chal-
lenges with methods, and future plans for patient involve-
ment. Although many hours of interview recordings were
collected, in this paper only the interview sections are dis-
cussed which are considered highly relevant and essential
to answer our research questions. The selection of
interview sections was based on the themes which were
derived from the interviews.
Why did developers involve patients?
Motivation for involving patients There are many rea-
sons why developers felt that they had to include pa-
tients. Some developers involved patients because this
was required by the FDA. Many developers wanted to
understand how it feels to live with a certain disease or
condition. Furthermore, developers wanted to be sure
that their PROM covered all the important issues, was
relevant to patients and could easily be completed by pa-
tients. One developers said that it is the academic’s role
to voice what patients want and experience.
“I don't know what it is to live with rheumatoid
arthritis. They have fatigue caused by rheumatoid
arthritis, so I could not do it better on my own. I
would say that we are the voice of the patient. The
patients know what they want and we as academics
have to be their voice and develop it. But it has to
come from them.”
One researcher gave an example illustrating why it is
important that PROMs are relevant to patients:
“It is called a generic measure (EQ-5D), but of course
the five aspects of health that are selected are more
relevant to some conditions than they are to others. So
someone with macular disease, whose sight is severely
impaired and registered as what used to be called
blind may appear to be in perfect health on the EQ-
5D, because it doesn't affect the five aspects of health
that are being asked about. Yet their quality of life is
shot to pieces, because they can't see. And yet, NICE
is demanding EQ-5D data from pharmaceutical
companies evaluating new treatments.”
Future plans for patient involvement Regardless of
how beneficial patient involvement was or how many
difficulties related to patient involvement PROM devel-
opers experienced, all PROM developers would recom-
mend patient involvement and wished to involve patients
again during their next PROM development.
“… it is like saying would you do research without a
statistician.”
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How are patients successfully involved in the development
of PROMs?
Requirements for patient involvement Successful pa-
tient involvement requires trained and/or experienced
staff, good communication, a clear understanding of
roles and expectations and awareness of a patient’s
limitations.
“I think the key thing once again is being clear from
the outset about roles and expectations around how
things work. We were very clear about that.”
Recruitment methods Most developers recruited pa-
tients in clinics or other health care centres. Other more
common options were charities and recruitment com-
panies. Most developers recruited until data saturation
was reached.
Recruitment challenges The biggest challenge of
recruiting patients was to achieve diversity, as finding
patients with certain characteristics could be difficult.
Examples of these characteristics were different cultures,
age groups or patients with disabilities. However, most
developers were confident that they had achieved a good
representation of the patient population.
“Well obviously by the end you knew you need to
find a 25 year old man and that is quite difficult in
arthritis. It is mostly middle-aged women and by the
end of it you are always looking for a young man at
the end.”
Another difficulty was getting patients to actually par-
ticipate. As patients are managing a personal life, work
life and an often time and energy consuming disease, pa-
tients are not always able to or interested in attending
interviews or focus groups. Developers therefore tried to
encourage participation by fitting appointments between
hospital appointments, offering lunch and keeping pa-
tients updated. One developer mentioned difficulties
with people lying about their condition as they then got
paid for participating. Another developer encountered
problems when he/she wanted to investigate an issue
that is taboo among a certain culture. Even if patients
were willing to participate, family members sometimes
kept them from participating.
Methods used to involve patients Most developers in-
volved patients during item development and while test-
ing the PROM for comprehensibility. The most used
methods to do this were interviews and/or focus groups.
Sometimes focus groups were organised online. Slightly
less common but still much used methods were cognitive
interviews and feedback questionnaires. Some developers
involved patients as patient research partners. When
asked to choose their preferred method, most developers
said that this is impossible as the methods serve different
purposes and complement each other.
Method motivation Many researchers used scientific
guidelines or standards as a guide for patient involvement.
“I mean, our whole development process has been
informed by FDA guidelines, so that is how we decided
to use the methods we have used. The FDA guidelines
are exactly that. They are guidelines. They are not
strict rules so they are open to certain amount of
interpretation. But certainly our development process
complies with their guidelines.”
Literature, personal preferences and experiences and
practical considerations such as how much time or
money it costs and how difficult it is to organise also
influenced the method of patient involvement. Focus
groups were sometimes chosen because they were an
easier and cheaper way to receive the input from many
patients at once.
“The reason why we choose focus groups for […] was
in part driven by cost implications, because it makes
it easier to include a larger number of patients for
less cost.”
Additionally, the interaction between patients was
greatly appreciated as developers thought that it would
result in different or more information than interviews.
Interviews, however, were chosen because they offered
a one on one opportunity with the patient. This not
only made it more suitable for private subjects, but it
also resulted in richer data.
“We’ve always done individual interviews because
we find we get a lot better, or more information, rich
information.”
Furthermore, developers considered interviewing an
easier method to involve patients.
Challenges with methods Although developers re-
ported few difficulties with interviewing, a developer did
mention that it can be challenging if a patient is not very
reflective or talkative and that patients can get off-track.
However, developers experienced more difficulties with
focus groups. Focus groups mainly suffered under dom-
inant patients taking over the focus group and patients
getting off-track. These problems were solved by re-
moving a patient, intervene verbally or use experienced
moderators.
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“We would actually move that patient out of the
focus group, if we couldn’t stop them any other way.
Sometimes these are personality traits, and it’s not
that we’re there to blame that person, so we might
then have to help to say this, very difficult patient,
mister X, you’ve got such comprehensive views on this,
I think it would be very helpful if you came with me
and sat with me in a separate room and tell me all
about this.”
What do patients contribute to the development of PROMs?
Patients mainly contributed to the questionnaire devel-
opment by helping to increase the validity and compre-
hensibility of the PROM. Patients were able to offer a
different perspective than physicians.
“In diabetes care until five years ago if you asked any
clinician or diabetologist: “How important are non-
severe hypoglycaemic events?” They would say: “Not
important at all. Drink a glass of orange juice. You are
fine.” We don’t even think about it. But by talking to
patients we found out that non-severe events had a
huge impact on patients’ functioning and well-being.
Because after they drink the orange juice they still feel
terrible for 20 h.”
Involving patients ensured that the PROM was rele-
vant to patients, and that patients were more likely to
complete the PROM.
“We hadn't asked any questions about changes in
medication in the PROM before and after treatment.
Some patients put notes on their responses saying: “I
have been able to stop taking my medication”, which
was something we hadn't considered.”
Many developers also highlighted that it is a great ex-
perience for patients as patients can share experiences
with each other, learn from each other, and also feel
valued by being involved.
“Yeah, you know, I think especially for the focus
groups. We found that people tended to have a very
positive experience. We definitely had people who
even, after the groups would exchange contact
information with each other.”
What are negative aspects of patient involvement?
On the downside involving patients is time consum-
ing, logistically challenging and impacts the budget.
It can also add to the complexity of the research
project and can be difficult to report. Furthermore,
involving patients may be upsetting for both patient
and developer.
“So again from the practical viewpoint it is financially
and time consuming. And as I said it was upsetting in
some cases, but I think overall we felt that patients
were getting a lot out of it.”
Some developers also mentioned that patients were
only able to reflect their own, personal perspective,
which could influence the relevance of the research if
only a few patients were involved and/or if a patient was
involved extensively. These challenges however, would
not deter most developers from involving at least a few
patients.
Why did some developers choose not to involve patients?
The PROM developers who refrained from involving
patients mainly did so because they either did not have
the time and resources or did not expect to gain any-
thing. Even though their aim was to develop a PROM,
one developer said that they did not aim to capture the
patients’ perspective. Another developer considered pa-
tient involvement unnecessary as the disease was well
documented. Additionally, he/she felt, based on earlier
experiences, that patients mostly just added subjective
impressions of single patients.
“From earlier questionnaire developmental processes
we got the impression that patient involvement
introduced several additional aspects. However, many
of those aspects were very subjective impressions of
single patients without significant impact on the
questionnaire.”
Plans for patient involvement in future developments
Even though not all developers were convinced of the
need to involve patients during PROM development,
all developers thought that patient involvement could
be beneficial, dependent upon circumstances such as
the aim of the questionnaire and the availability of
resources. Therefore they would consider involving
patients next time.
Discussion
As the importance of patients’ knowledge on health and
health care as a source for improving the quality of care
is increasingly recognised [2, 4, 11], PROMs are used
more and more [1, 2, 4]. Although for capturing pa-
tients’ perspectives on health care patient involvement
in PROM development is deemed necessary [8–12], pa-
tients are still not always involved [24]. There is not
one correct procedure for involving patients [27] and
choosing between patient involvement and no patient
involvement can be difficult as both can have conse-
quences for the research project. This study therefore
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aimed to give more insight into PROM developers’ ex-
periences with patient involvement by first investigating
how patients are involved in the development process.
Patients were mostly recruited via clinics or health pro-
fessionals until data saturation was reached. Recruiting
until data saturation has been reached is a method in
qualitative research that is widely accepted and used by
many researchers [32, 33]. The developers mostly in-
volved patients using interviews and focus groups. These
methods are mentioned by several scientific standards or
guidelines as fitting methods to involve patients [28, 34].
Although some developers indicated that they adapted
the recommended methods to their patient group or to
how they thought it would work better, many followed
the guidelines or used methods which were the most
practical and/or cheapest, or based their choice on per-
sonal experiences and preferences.
Besides the more common methods used to involve
patients, several developers involved patients especially
in their more recent PROM developments as patient
research partners or included patients in steering or ad-
visory groups. Even though this more collaborative
form of patient involvement may have some issues that
need to be dealt with, such as the amount of experience
and skills patients would need to actively participate
[35] and whether patients who are able to participate to
such an extent are good representatives of the patient
group [36], it is considered an important step forward
for patient involvement in PROM development [12].
Another less common but increasingly used method
concerns conducting qualitative research on the internet.
As many people use the internet, conducting qualitative
research online can be helpful in gathering the opinions
of many patients [37]. Patients with rare conditions can
also be more easily reached [38] and communicating
online may offer patients more freedom to express
themselves [39]. Online qualitative research also has
some drawbacks. For example, you are only able to
study a select group of patients as patients need to have
access to internet and certain skills to participate on
the internet [40, 41]. Additionally, it is much less clear
what the rules are regarding informed consent and
what is considered a private conversation and what is
not [37]. As both online and face to face qualitative
methods have several pros and cons, a decision for ei-
ther of these methods should be made separately for
each study.
Besides how patients are involved in PROM develop-
ment, the present study also investigated what patient
involvement contributes towards the PROM develop-
ment. Patients contributed by offering their experiences
and views regarding living with a disease. These views
not only helped increase the validity and comprehensi-
bility of the PROM, but also helped to ensure that the
PROM was relevant for other patients. The benefits of
patient involvement were very important to PROM de-
velopers as most would not consider to refrain from in-
volving patients, even if they did not really have the
budget or the time to do it.
Although most PROM developers were overwhelmingly
enthusiastic about patient involvement, negative aspects
and costs of patient involvement were encountered at sev-
eral levels. Most developers experienced some difficulties
finding enough diverse patients and getting patients to
fit research into their lives could be challenging. Further-
more, actually involving patients could be challenging as
most developers encountered patients who dominated
the conversation or easily went off-track. Overall, patient
involvement was time consuming, made an impact on
the budget and was logistically challenging. Although
the costs of patient involvement are sometimes recog-
nised in the literature as a challenge of qualitative re-
search [12], the challenge of actually recruiting and
involving patients and the time it takes to do it well
should also be acknowledged.
It should therefore come as no surprise that a lack of
resources was one of the reasons why not all PROM de-
velopers involved patients. There were however also a
few PROM developers who did not see any added bene-
fit of patient involvement for their PROM. As patient
involvement is increasingly required by organisations
such as the FDA [34], these PROM developers may not
have this choice for much longer.
Limitations and strengths
Some limitations need to be taken into account. First,
this study aimed to give insight into the views of both
developers who involved patients and developers who
did not involve patients. However, only a low number of
PROM developers who did not involve patients were
willing to answer our questions.
Second, only 58.5% of the invited PROM developers
who did involve patients agreed to participate in our
study. As we indicated in our invitation that we wished
to discuss patient involvement in PROM development,
it is possible that the PROM developers who agreed to
participate were perhaps more enthusiastic about pa-
tient involvement than the PROM developers who did
not reply. Whether we received a reply was in any case
not related to how long ago the paper was published,
as no difference was found between the publication
dates of developers who participated and developers
who did not participate. However, developers may have
felt unsure about discussing their research in a lan-
guage other than their native language, as all but one
non-native English speakers declined our invitation.
This makes it difficult to generalise the results beyond
English speaking countries.
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Third, results may be influenced by a confirmation
bias. As patient involvement costs time, resources and
effort, developers must have been very motivated to in-
volve patients. This may also mean that they are more
focused on the positives.
Fourth, although by including both co-authors in the
analysing process efforts were made to guard the trans-
parency and reliability, results may be coloured by views
held by the first author who interviewed the developers
and was the main coder.
An important strength of this study is that we were
able to offer an insight into the views of many both ex-
perienced and less experienced PROM developers who
worked with a number of patient groups and developed
a PROM fairly recently. This study was therefore able to
not only give insight into the methods used to recruit
and involve patients, the many pitfalls and benefits of
patient involvement, but also into the general opinion
held by PROM developers regarding patient involvement
in PROM development.
Implications
The results of this study have several implications for
patient involvement in PROM development. First, this
study indicates that patient involvement requires the
availability of resources such as time and money. A lack
of or limited resources may keep developers from opti-
mally involving patients or it may keep them from involv-
ing patients at all. As patient involvement is included in
some scientific guidelines [28] and the Food and Drug
Administration even requires it [34], it is essential that the
necessary resources are included in the costs and the
duration of the study when applying for subsidies so this
can no longer be a stumbling block.
This is especially important as not involving patients
may have implications for the use of the PROM. It
may impact the response and the validity of the PROM
[13, 20]. Perhaps more importantly, PROMs are used for
important purposes, such as measuring the performance
of health care providers [2–5]. Not involving patients
may mean that health care providers are judged on as-
pects of care which may not be important to patients,
while important aspects may be forgotten. Furthermore,
research shows that health care providers especially try
to improve on the performance aspects they scored less
well on [42]. If performance measures are used which do
not reflect what patients consider important, health care
providers may neglect to improve on aspects of care
which are important to patients. Because of the possible
consequences of using PROMs which do not reflect the
patient’s perspective adequately, patient involvement
should be taken very seriously.
Furthermore, the results suggest that many developers
keep to scientific guidelines for methodological decisions
or alternatively pick methods to involve patients which
are most practical to them or which suit their personal
preferences. Guidelines may be a good place to start as
it guarantees a certain level of patient involvement and
practical solutions should certainly not be completely
disregarded as it helps developers involve patients within
their limitations. However, as there is no perfect method
for involving patients [27], it may be more beneficial that
pros and cons of the available methods are considered.
For example, based on our results, interviews may be es-
pecially fitting for discussing intimate or taboo subjects.
Focus groups may be helpful to learn about the majority
view or if you have a very tight budget. Both also have
drawbacks such as the difficulty of keeping a focus group
on track, or the single subjective view of a patient during
interviews. It is therefore important that a method is
picked based on what is most suitable for the patient
group and the purpose of the study.
Fourth, several PROM developers mentioned the im-
portance of good qualitatively trained and/or experi-
enced staff for moderating focus groups or conducting
interviews. They also highlighted the importance of
good communication, a clear understanding of roles
and expectations and awareness of patient’s limitations.
These requirements combined with the difficulties one
may experience while interviewing or conducting focus
groups asks a lot of the persons who are hired to do so.
Adequately training staff to deal with patients and con-
duct qualitative research may be imperative for success-
ful patient involvement and optimal patient benefits for
the PROM development.
Conclusion
Even though patient involvement may be difficult at
times as it is costly, time consuming, logistically challen-
ging and some patients can be hard to handle, all PROM
developers who involved patients during PROM develop-
ment agree that patient involvement in PROM develop-
ment is necessary. Patient involvement results in a more
valid and comprehensible PROM which is more relevant
to patients. Although most developers are united in their
enthusiasm for patient involvement, a lack of resources
can be a stumbling block. Additionally, this enthusiasm
for patient involvement does not appear to stretch out
towards choosing the methods for involving patients.
Most developers follow guidelines or standards or choose
a method based on personal experience or practicalities.
They do not always appear to actively consider pros and
cons of different methods that can be used to involve
patients. Although guidelines for PROM development,
personal experience and practicalities may be a good place
to start, to optimize patient involvement developers
should explicitly think about which methods would suit
their study and the patient population of interest.
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